Editorial: Drug Design in the Context of Cancer Recent Advancements

Cancer is an increasing explanation for morbidity and mortality in most countries. It’s recently overtaken heart condition because the commonest explanation for death within the UK. “Breakthroughs” in cancer research are reported regularly within the media. Some reports are supported new results that show potential for improved treatments, but others are premature or publicity seeking, and therefore the motivation behind them is questionable. The general public has high expectations that basic science cancer research will translate into improved cancer cures and care. Yet awareness and understanding of the clinical trials that are essential in establishing the effectiveness of latest treatments is restricted. Recruitment to randomized clinical trials evaluating new cancer treatments is usually slow, partly because people are convinced that each one new treatments are likely to be an improvement and partly due to unease about the method of randomization. Better public education about categories of evidence in reference to health interventions might contribute to speedier and more appropriate evaluation of promising treatments. Public confidence that cancer care within the Uk is perfect has been shaken by reports that outcomes for a few common cancers differ in countries in western Europe, which survival rates in Britain for 18 of 25 cancer types studied are poorer than in most other European countries. Better than average outcomes were seen in Switzerland, Finland, and Holland. These reports, alongside evidence that cancer survival rates differ within a rustic consistent with the pattern of care, prompted review of the supply of look after cancer patients within the Uk and in parts of Australia. Optimal organization of cancer care might achieve appreciable gains. Within the case of carcinoma, this might amount to a 5% improvement within the survival rate at five years. Such a gain would be viewed as a serious breakthrough if it were the results of a replacement treatment.

Recent advances

• Multidisciplinary treatment teams specializing in specific organ sites are recognized as being important for optimal cancer care and for improving outcome.
• The organization and delivery of supportive care to patients with cancer has improved.
• Treatment goals are more clearly defined.
• Public awareness and understanding of the clinical trials that are driving clinical research has increased.
• Research has started on potential treatments like matrix metalloproteinase inhibitors, gene therapy, and cancer vaccines.

New treatments

Improved understanding of the biology of cancer will ultimately mean that the present, empirically derived cytotoxic drugs and radiotherapy are going to be superseded by cancer treatments supported specific genetic and phenotypic abnormalities in cancer cells. Though this goal remains a dream, advances in cancer biology are identifying targets for brand spanking new treatments, and a few of those will convince be the Achilles’ heel of cancer cells.

Drug Designing: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Drug Designing: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Editorial tracking submission: https://www.longdom.org/submissions/drug-designing-open-access.html

Nancy Ella
Editor Board
Drug Designing: Open Access
drugdesign@eclinicalsci.org